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Abstract: Protein phosphorylation is the most abundant post-translational modiﬁcation in cells. Src homology 2 (SH2) domains speciﬁcally recognize phosphorylated tyrosine (pTyr) residues to mediate signaling
cascades. A conserved pocket in the SH2 domain binds the pTyr side chain and the EF and BG loops
determine binding speciﬁcity. By using large phage-displayed libraries, we engineered the EF and BG loops
of the Fyn SH2 domain to alter speciﬁcity. Engineered SH2 variants exhibited distinct speciﬁcity proﬁles
and were able to bind pTyr sites on the epidermal growth factor receptor, which were not recognized by
the wild-type Fyn SH2 domain. Furthermore, mass spectrometry showed that SH2 variants with additional
mutations in the pTyr-binding pocket that enhanced afﬁnity were highly effective for enrichment of diverse
pTyr peptides within the human proteome. These results showed that engineering of the EF and BG loops
could be used to tailor SH2 domain speciﬁcity, and SH2 variants with diverse speciﬁcities and high afﬁnities
for pTyr residues enabled more comprehensive analysis of the human phosphoproteome.
Statement: Src Homology 2 (SH2) domains are modular domains that recognize phosphorylated tyrosine embedded in proteins, transducing these post-translational modiﬁcations into cellular responses.
Here we used phage display to engineer hundreds of SH2 domain variants with altered binding speciﬁcities and enhanced afﬁnities, which enabled efﬁcient and differential enrichment of the human phosphoproteome for analysis by mass spectrometry. These engineered SH2 domain variants will be useful
tools for elucidating the molecular determinants governing SH2 domains binding speciﬁcity and for
enhancing analysis and understanding of the human phosphoproteome.
Keywords: SH2 domain; phage display; protein engineering; phosphoproteomics

Abbreviations: ELISA, enzyme-linked immunosorbent assay; GST, glutathione S-transferase; MS, mass spectrometry; pTyr, phospho-tyrosine; SH2, Src Homology 2 domain.
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Introduction
Cell signaling relies on highly coordinated and regulated networks of protein–protein interactions to efﬁciently
respond
to
environmental
stimuli.1
Phosphorylation, the addition of a phosphate group
to a protein, is the most frequent post-translational
modiﬁcation,2 and it acts as a molecular switch to
regulate dynamic protein–protein interactions.
To identify phosphorylated targets and assess
phosphorylation states, cells rely on specialized modular domains that bind to speciﬁc phosphorylated
sequences in proteins.3,4 In metazoans, members of
the large Src Homology 2 (SH2) domain structural
family control cellular signaling cascades by binding
with moderate afﬁnity to speciﬁc phosphorylated
tyrosine (pTyr) residues in proteins.5 The expansion
of the SH2 domain repertoire appears to have
enabled an increased sophistication in pTyr-mediated
signaling,5 and in turn, this may have facilitated the
transition from unicellular to multicellular organisms.6 For example, the unicellular yeast Saccharomyces cerevisiae contains only a single SH2 domain,7
whereas 112 human proteins contain 122 SH2
domains, which regulate numerous signaling pathways that are essential for normal cell function and
have been implicated in many diseases.8,9
The SH2 fold is comprised of a β-sheet ﬂanked by
two alpha helices [Fig. 1(a)]. The recognition of a
pTyr peptide ligand by an SH2 domain can be
described as being two-pronged, wherein a conserved
Arg residue at the base of the pTyr-binding pocket
coordinates the pTyr side chain, and a cleft on the
surface of the domain interacts with other ligand residues to confer speciﬁcity [Fig. 1(b)].7,10,11 Interactions
with the pTyr side chain contribute roughly half of
the total free energy of the SH2–ligand interaction,12
and interactions are typically of moderate afﬁnities
in the low micromolar range.13 Aside from the conserved interactions with the pTyr side chain, additional interactions between the SH2 domain are
mediated mainly by the variable EF and BG loops,
which ﬂank the hydrophobic cleft and deﬁne speciﬁcity for residues C-terminal to the pTyr.11,14
Many structural studies and screens with phosphopeptide libraries have investigated the binding
speciﬁcities of SH2 domains,15,16 which have been
shown to recognize three major types of ligands17–20
and have been grouped into three corresponding speciﬁcity classes. Class 1 domains are deﬁned by speciﬁcity for the consensus pYξξΦ (where ξ and Φ denote
hydrophilic and hydrophobic residues, respectively),
and are further divided into four subgroups, with
Class 1c domains recognizing an asparagine at the
second position following pTyr, (P + 2, pY-x-N). In
Class 1c domains, exempliﬁed by the Grb2 SH2
domain, a bulky residue at the ﬁrst position of the EF
loop (Trp121) blocks access of the ligand to the binding
pocket, forcing it to adopt a Type I β-turn that
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enables contact with an Asn residue at P + 2 [Fig. 1
(c)].14,21 Class 2 domains preferably recognize a proline or aliphatic residues (Ψ) at the third position following pTyr (P + 3, pY-x-x-P/Ψ). For example, in the
the Fyn SH2 domain (Fyn-SH2), the EF loop adopts
an open conformation enabling access of a hydrophobic P + 3 residue to the hydrophobic cleft, while
Leu239 in the BG loop blocks the P + 4 binding pocket
[Fig. 1(d)].14,22 Class 3 domains recognize a hydrophobic residue at the fourth position following pTyr
(P + 4, pY-x-x-x-Φ).17 The BRDG1 SH2 domain exempliﬁes a Class 3 domain, in which Leu240 blocks the
P + 3 binding pocket and an open P + 4 pocket accommodates a Leu side chain from the ligand
[Fig. 1(e)].14
Since the EF and BG loops work together to dictate SH2 domain speciﬁcity by controlling access to
binding pockets, we employed a phage display
approach that diversiﬁed these loops to develop SH2
domain variants with altered speciﬁcities. We generated libraries of Fyn-SH2 variants with diverse EF
and BG loops and screened for binding to a panel of
pTyr peptides representing diverse speciﬁcities. We
proﬁled the binding speciﬁcities of selected Fyn-SH2
variants and identiﬁed altered binding speciﬁcities
that enabled recognition of ligand classes that were
not recognized by wild-type Fyn-SH2 (Fyn-SH2.wt).
When used for the analysis of the human phosphoproteome by mass spectrometry, Fyn-SH2 variants
with altered speciﬁcities enabled the isolation of distinct phosphorylated proteins, conﬁrming the robustness of loop engineering for reshaping SH2 domain
speciﬁcity.

Results
Fyn-SH2 variants with altered binding
speciﬁcities
The EF and BG loops work together to dictate pTyr
ligand selectivity of SH2 domains.14 Thus, to modulate speciﬁcity, we created two phage-displayed
libraries of Fyn-SH2 variants in which positions
within the EF and BG loops were diversiﬁed with
degenerate codons encoding for all 20 genetically
encoded amino acids [Fig. 1(a)]. In both libraries,
three codons within the EF loop were replaced by
three degenerate codons. The two libraries differed in
that three codons in the BG loop were replaced by
either three degenerate codons (Library 1) or by zero
to ﬁve degenerate codons (Library 2). Length variation was introduced in the BG loop of Library 2 based
on the observation that longer BG loops in some SH2
domains contribute to extended binding surfaces that
improve interactions with pTyr ligands.23,24
To assemble a panel of SH2 variants with diverse
speciﬁcities, the two libraries were cycled through
rounds of binding selections with 19 biotinylated
pTyr peptides immobilized on streptavidin-coated
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Figure 1. Fyn-SH2 library design. (a) The Fyn-SH2 main chain is shown as a gray ribbon, the main chain of the pTyr peptide ligand
(EPQpYEEIPIYL) is colored orange (PDB entry 1AOU), and the pTyr side chain is shown as sticks colored red. Residues that were
diversiﬁed in the library are shown as numbered spheres colored green (EF loop) or blue (BG loop). In Libraries 1 and 2, the
codons encoding the three BG loop residues were replaced by three or zero to ﬁve degenerate codons, respectively, and in both
libraries, the codons encoding the three EF loop residues were replaced by three degenerate codons. (b) Surface representation of
Fyn-SH2 in complex with the pTyr peptide ligand (PDB entry 1AOU). The EF and BG loops are colored green or blue, respectively.
The conserved Arg176 that coordinates the pTyr side chain (red sticks) is colored cyan. Residues forming the hydrophobic cleft
interacting with the ligand are colored purple. The peptide ligand backbone is shown as an orange tube and side chains are
shown as sticks. (c–e) Surface representations of the SH2 domains of (c) Grb2 (PDB entry 3WA4), (d) Fyn (PDB entry 1AOU) and
(e) BRDG1 (PDB entry 3MAZ) in complex with P+ 2N (SDpYMNMTP), P+ 3I (EPQpYEEIPIYL) or P+ 4L (ANSpYENVLIAK) ligands,
respectively. SH2 domain surfaces and peptide ligands are shown and colored as in Panel B, and in addition, key residues in the
EF and BG loops that dictate speciﬁcity are colored yellow.

plates, which represented diverse natural ligands
spanning the known speciﬁcity classes (Table I). Following ﬁve rounds of selections, positive clones were
identiﬁed by clonal phage ELISAs as those that
exhibited strong signals on wells containing immobilized pTyr peptides but not on wells containing streptavidin only. Approximately 12 positive clones from
each library selected against each peptide were subjected to DNA sequencing, resulting in a total of
152 unique Fyn-SH2 variants (Fig. 2 and Table S1).
In accordance with the library designs, the variants
contained diverse sequences only in the EF and BG
loops, and signiﬁcant length diversity was observed
in the BG loop region. In many cases, sequence consensus was observed amongst variants from binding
selections for the same peptide, and also, amongst
variants selected against peptides of the same class,
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indicating that these variants likely use similar binding mechanisms (Fig. 2).

Afﬁnity and speciﬁcity analysis of Fyn-SH2
variants
We characterized in detail Fyn-SH2.wt and six variants that were chosen to represent diverse loop
sequences and binding preferences (Table II). We
assessed the afﬁnities and speciﬁcities of the domains
by ﬂuorescence polarization with a series of pTyr peptides covering a broad range of speciﬁcity classes
(Table III). The panel included three peptides representing a prototypical P+ 2N, P+ 3I or P+ 4L ligand,
and four peptides representing pTyr sites in the epidermal growth factor receptor (EGFR). Fyn-SH2.wt
bound to all the prototypical peptides with afﬁnities
that agreed with values previously reported for
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Table I. pTyr Peptides used for Fyn-SH2 Variant Selections
Peptides
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Sequence
E
T
E
E
P
A
D
D
V
Q
E
A
E
Q
N
R
S
N
N

P
T
N
S
Q
D
P
H
P
P
P
E
P
D
P
N
N
P
P

Q
E
L
I
R
E
H
Q
E
E
L
L
Q
T
D
D
F
V
E

pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY
pY

E
S
E
E
L
L
Q
Y
I
V
L
S
E
E
Q
D
R
H
L

E
E
G
V
V
I
D
N
N
N
N
N
E
T
Q
D
A
N
N

I
I
L
L
I
P
P
D
Q
Q
T
A
E
H
D
T
L
Q
T

E
K
N
G
Q
Q
H
A
S
A
F
A
L
L
F
I
M
P
V

E
I
L
M
G
Q
S
P
V
D
A
P
E
E
F
P
D
L
Q

–
H
D
Q
D
G
T
G
P
V
N
V
–
T
P
I
E
N
P

–
T
D
Q
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

Binding Class

Motif

Source

2
2
2
2
2
2
2
1c
1c
1c
1c
1c
3
3
3
3
3/4
1c/3
1c/3

P + 3I
P + 3I
P+3L
P+3L
P + 3I
P + 3P
P + 3P
P+2N
P+2N
P+2N
P+2N
P+2N
P+4L
P+4L
P + 4F
P + 4I
P + 3 L, P + 4 M
P + 2 N, P + 4P
P + 2 N, P + 4 V

TM antigen
SIG11 pY668
CD79A pY188
CEA20 pY578
EGFR pY978
EGFR pY1016
EGFR pY1125
ShcA pY239
EGFR pY1138
ErbB2 pY1139
ErbB4 pY1208
PDGFRβ pY716
TM antigen
TRAF7 pY275
EGFR pY1172
MALT1 pY470
EGFR pY998
EGFR pY1092
EGFR pY1110

The sequences of each pTyr peptide used as bait in phage display experiments are reported. Gray shading highlights residues
deﬁning the binding class and speciﬁcity motif are indicated. Each peptide was derived from a natural protein source, as indicated. The following abbreviations are used: TM antigen, polyomavirus middle T-antigen; SIG11, sialic acid-binding Ig-like
lectin 11; CD97A, cluster of differentiation 97A; CEA20, carcinoembryonic antigen-related cell adhesion Molecule 20; EGFR,
epidermal growth factor receptor; ShcA, Src homology and Collagen A; ErbB2, receptor tyrosine-protein kinase erbB-2;
ErbB4, receptor tyrosine-protein kinase erbB-4; PDGFRβ, beta-type platelet-derived growth factor receptor; TRAF7, TNF
receptor associated Factor 7; MALT1, Mucosa-associated lymphoid tissue lymphoma translocation Protein 1.

similar peptides,14,25 but it did not bind to any of the
EGFR peptides. Each variant bound to the peptide it
was selected for and exhibited distinct binding speciﬁcity proﬁles that ranged from the broad speciﬁcity of
v29, which recognized six of seven peptides, to the
highly speciﬁc v17, which recognized its cognate peptide only. Taken together, the ﬂuorescence polarization and peptide array assays showed that we
succeeded in generating SH2 domain variants with
diverse speciﬁcities by altering EF and BG loop
sequences.

Phosphoproteome enrichment with Fyn-SH2
variants
Because SH2 domains bind to pTyr proteins and peptides, they can be used as afﬁnity reagents for the
enrichment of phosphoproteomes for mass spectrometry (MS) analysis. However, these applications have
been limited by the modest afﬁnities of natural SH2
domains.26 We previously developed “superbinder” Fyn
and Src SH2 domains with high afﬁnities for a broad
spectrum of pTyr peptides by mutating three residues
in the pTyr-binding pocket.27 Recently, these superbinders have been used for ultra-deep MS analysis of
phosphoproteomes.28,29 To advance this methodology,
we investigated whether coverage of the human phosphoproteome could be improved further by combining
superbinder mutations with our loop variants to
develop SH2 domains with diverse speciﬁcities and
high afﬁnities for pTyr peptides. We engineered
superbinder versions of Fyn-SH2.wt (Fyn-SH2.s) and
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ﬁve variants (v5s, v25s, v27s, v28s, v29s), and conﬁrmed high afﬁnity binding to a panel of pTyr peptides
by ﬂuorescence polarization assays (Table IV).
We compared Fyn-SH2.wt, Fyn-SH2.s and three
of the superbinder variants (v5s, v25s, v28s) for the
ability to enrich phosphorylated peptides from
orthovanadate-treated HeLa cells for MS analysis
[Fig. 3(a)]. Proteins in cell lysates were digested with
trypsin, labeled with tandem mass tags, captured
with SH2 domains, and subjected to MS analysis. All
superbinders greatly enhanced the enrichment of
phosphopeptides compared with Fyn-SH2.wt, and
Fyn-SH2.s exhibited the broadest pTyr peptide coverage [Fig. 3(b)]. Despite their high sequence similarity
(Table II), the analyzed superbinder Fyn-SH2 variants exhibited different proﬁles for enrichment of
pTyr peptides [Fig. 3(b)]. Correlation analysis showed
that v5s and v28s isolated phosphopeptides in a very
similar manner, whereas v25s and v28s showed the
highest degree of difference (Fig. S1). This is consistent with the high sequence similarity of the BG
loops of v5s and v28s (Table II), indicating that these
loops may control access to the binding pocket in a
similar manner.
This was further assessed by comparing the peptide sets that were commonly isolated by different
variants. In comparison to v25s, v5s and v28s isolated 18 and 16 pTyr peptides more efﬁciently, and
shared 55% of these [Fig. 3(c), top left], thus conﬁrming similar binding speciﬁcities (Fig. S1). When compared to v28s, v25s and v5s showed a 36% overlap,

SH2 Domain Variants with Altered Binding Speciﬁcity

Peptide

Motif

n

Logo
EF loop

1

Class
2

P+3I

5

3

P+3L

14

4

6
8

Class
3

P+3L
P+3I
P+3P
P+2N

P+2N

14

11

P+2N

11

12

P+2N

2

13

P+4L

14

17
18
19

P+4F
P+4F
P+3L/
P+4M
P+2N/
P+4P
P+2N/
P+4V

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

216 217 218

236 237 238 A

B

20

10

15

B

6

8

P+4L

236 237 238 A

4

P+2N

14

216 217 218

4

9

16

Not
defined

11

2

5

Class
1c

P+3I

BG loop

2
8
3
3
15
7

Figure 2. Sequence conservation of Fyn-SH2 variants. A total
of 152 unique Fyn-SH2 variants were grouped into ﬁve classes
according to the nature of the pTyr peptide used for their
selection from phage-displayed libraries (Table I). A number of
unique variants isolated for each peptide (n) were aligned and
the alignments were used to derive sequence logos from the
EF and BG loop amino acid frequencies using the WebLogo
tool.47 Only one variant was selected for Peptide 7, and thus, a
logo could not be determined in this case.

indicating a moderately similar speciﬁcity [Fig. 3(c),
top middle]. In contrast, none of the pTyr peptides
that v25s and v28s enriched more efﬁciently than v5s
were shared [Fig. 3(c), top right], conﬁrming very different binding speciﬁcities (Fig. S1).
Similar patterns were observed for peptide sets
with a log2-fold enrichment lower than a reference
Fyn-SH2 variant [Fig. 3(c), bottom], proving that all
three domains have signiﬁcant speciﬁcity differences.
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In a second experiment, we ﬁrst captured intact
proteins with an SH2 domain, digested with trypsin,
and then performed MS analysis.
For 427 proteins that were log2-fold or greater
enriched for Fyn-SH2.s relative to negative control
beads, we compared peptide abundance for each of
the SH2 domains and an anti-pTyr antibody relative
to Fyn-SH2.s [Fig. 3(d)]. This analysis showed that
Fyn-SH2.wt and the anti-pTyr antibody poorly captured most of the proteins isolated by Fyn-SH2.s.
Moreover, a superbinder version of the Grb2 SH2
domain (Grb2-SH2.s) and the ﬁve superbinder FynSH2 variants exhibited signiﬁcant differences in the
capture efﬁciency for these proteins, amongst themselves and in comparison with Fyn-SH2.s. Many of
the proteins were less efﬁciently captured by
Grb2-SH2.s and the superbinder Fyn-SH2 variants
than by Fyn-SH2.s, but a subset was more efﬁciently
captured by particular domains [Fig. 3(d)]. Analysis
of this subset showed that only four proteins were
common to two or more variants (Table S2), indicating that the Fyn-SH2 variants have distinct speciﬁcity proﬁles, and that their combination could improve
the pTyr sequence coverage.
Taken together, these results show that superbinder SH2 domains are much more efﬁcient than
Fyn-SH2.wt or an anti-pTyr antibody for phosphoproteome enrichment. Moreover, they further highlight
the altered speciﬁcities of the Fyn-SH2 variants and
suggest that combinations of superbinder variants
with Fyn-SH2.s could serve as even more efﬁcient
phosphoproteome capture reagents than Fyn-SH2.s
alone.

Discussion
SH2 domains are key components of cellular signaling pathways,8,30 and they function by speciﬁc recognition of pTyr sites in partner proteins. In the context
of complex networks of kinases and phosphatases,
correct targeting requires highly specialized and speciﬁc interactions. The EF and BG loops of SH2
domains have been shown to be key elements responsible for conferring speciﬁcity.14 Although recognition
of pTyr sites is mainly achieved through interactions
of these loops with the residues C-terminal to the
pTyr moiety,31 these interactions are not the sole contributors to speciﬁcity, and recent studies have
revealed a higher degree of complexity.32
Substitutions within the SH2 domain core,
together with diversiﬁcation of EF and BG loop positions, enabled the development of an SH2 domain
with dual speciﬁcity.33 Moreover, incorporation of
non-natural amino acids at a core position demonstrated the importance of the core for dictating SH2
domain speciﬁcity.34 Single substitutions in the EF
and BG loops altered the speciﬁcities of Src,35
BRDG1 and Fyn SH2 domains,36 but the loops act
cooperatively and multiple mutations may greatly
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Table II. Fyn-SH2 Variants Subjected to Afﬁnity Assays
EF loop
Variants
Fyn wt
v5
v17
v25
v27
v28
v29

BG loop

216

217

218

236

237

238

a

b

Selection peptide

T
W
G
P
V
R
W

T
L
R
G
R
R
R

R
G
G
G
G
R
G

A
V
–
W
W
L
W

G
P
–
Y
Y
P
Y

L
G
–
W
W
G
W

–
S
–
–
–
–
–

–
–
–
–
–
–
–

9
13
5
6
7
15

Motif
P+2N
P+4L
P + 3I
P + 3P
P + 3P
P + 4F

Source
EGFR pY1138
TM antigen
EGFR pY978
EGFR pY1016
EGFR pY1125
EGFR pY1172

Sequences are shown for the EF and BG loop regions that were diversiﬁed in the libraries for variants that were subjected to
afﬁnity analysis (Tables III and IV). Insertions in the BG loop relative to Fyn-SH2.wt are labeled with letters, whereas
dashes indicate gaps in the alignment. The binding speciﬁcity motif and source of pTyr peptides used to isolate a speciﬁc variant in phage-display experiments are reported as in Table I.

expand the range of speciﬁcities that can be supported by the SH2 fold. Thus, we performed combinatorial diversiﬁcation of the EF and BG loops to more
extensively explore the potential for SH2 domain
speciﬁcity engineering.
Our approach was successful in generating
numerous Fyn-SH2 variants from selections for binding to 19 distinct ligands representing various speciﬁcity classes. Assays with ﬂuorescence polarization of
synthetic peptide ligands showed that many variants
exhibited altered speciﬁcities and this was further conﬁrmed by mass spectrometry. However, the observed
speciﬁcities did not always match the speciﬁcities
expected from the peptides used for selection, and
many domains exhibited broad speciﬁcities. Similar
binding proﬁles were previously encountered in studies of PDZ and SH3 domain variants derived by phage
display, where hundreds of variants were selected for
binding to diverse targets but the speciﬁcities were
typically broad.37–40 These issues may be addressed by
further optimization of library design and selection
strategies. In particular, including additional positions
beyond the EF and BG loops in the diversiﬁcation
strategy may yield domains that can establish more
precise contacts with ligands and thus confer greater
speciﬁcity. Moreover, selections can be made more
stringent by adding competitor peptides to the phage
pool to remove variants with broad or unwanted speciﬁcities, and by increasing the stringency of the washing procedures to remove less tightly bound variants.
Nevertheless, even with non-optimal library design
and selection strategies, we were able to generate FynSH2 variants with diverse speciﬁcities, as demonstrated
by the acquired ability of a number of Fyn-SH2 variants
in binding pTyr sites on EGFR. Therefore, the modulation of the EF and BG could be used as a general strategy to develop SH2 variants with tailored speciﬁcity to
rewire cell signaling pathways for synthetic biology. For
example, Fyn-SH2 variants able to bind clinically relevant pTyr sites on EGFR have the potential to compete
with dysregulated EGFR protein partners, thus disrupting aberrant signaling pathways.
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We converted Fyn-SH2 variants into superbinders with extremely high afﬁnities for pTyr peptides
simply by transferring three additional substitutions
from a previously engineered superbinder SH2
domain.27 As previously reported Fyn and other SH2
domains have the propensity to form dimers at elevated concentrations.41 However, given the low concentration range used in our binding assays, the high
binding afﬁnity observed is likely dependent on the
formation of an improved pTyr-binding pocket.
We were able to use the superbinder Fyn-SH2
variants to enrich for diverse sequences within the
human phosphoproteome with much greater efﬁciency than with Fyn-SH2.wt or an anti-pTyr antibody. Furthermore, different Fyn-SH2 variants
exhibited distinct patterns of enriched sequences,
suggesting that combinations of superbinder SH2
variants with distinct binding selectivity are likely to
be even more effective than single superbinders for
broad enrichment of the phosphoproteome for MS
analysis. Thus, by applying improved strategies for
speciﬁcity engineering with established means for
making superbinders, it should be possible to develop
an optimized toolkit of SH2 superbinder variants tailored for phosphoproteome research.

Methods
Library construction and selection of Fyn-SH2
variants
For the construction of phage-displayed libraries,
combinatorial site-directed mutagenesis of a phagemid designed for the phage display of Fyn-SH2 was
performed.
Positions in the EF and BG loop sequences were
simultaneously mutated with a “hard randomization”
strategy, as described.42 Libraries were constructed
by oligonucleotide-directed mutagenesis,43 using a set
of mutagenic oligonucleotides containing degenerate
NNK (N = A/G/C/T, K = G/T) codons at positions to be
diversiﬁed.
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Afﬁnities were determined by ﬂuorescence polarization. Gray shading indicates the pTyr peptide that was used in binding selections from which each variant was obtained (selection peptide, reported as in Table I). Dashes indicate no detectable binding. Sequences of the variants are shown in Table II.
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Table IV. Afﬁnities of Superbinder Fyn-SH2 Variants for Synthetic Peptides
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in binding selections are indicated as in Table I. Dashes indicate no detectable binding. Sequences of the variants are shown in Table II.
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Table III. Afﬁnities of Fyn-SH2 Variants for Synthetic Peptides

Figure 3. Enrichment of the human phosphoproteome with superbinder Fyn-SH2 variants. (a) Workﬂow of pTyr peptide
enrichment by superbinder Fyn-SH2 variants. Proteins from orthovanadate-treated HeLa cells were digested with trypsin, and
peptides were labeled with 10-multiplex tandem mass tags (TMTs). TMT-labeled pTyr peptides were enriched by an immobilized
superbinder Fyn-SH2 variant, eluted, pooled and analyzed by LC–MS/MS. (b) Heat map depicting un-supervised clustering of
99 pTyr peptides enriched by Fyn-SH2.wt or superbinder Fyn-SH2 variants. Samples were analyzed in duplicate in two
independent experiments (a,b). (c) Venn diagrams comparing the pTyr peptide enrichment proﬁles of superbinder Fyn-SH2
variants v25s, v28s, and v5s. The top and bottom diagrams show pTyr peptide sets with log2-fold higher or lower enrichment,
respectively, than the reference variant that is indicated above each pair of diagrams. (d) Un-supervised clustering of
phosphoproteins pulled down by an anti-pTyr antibody, Fyn-SH2.wt or superbinder SH2 variants, prior to trypsin digestion and
labeling with TMT. As a control for non-speciﬁc binding, TMT-labeled peptides were loaded onto the resin used to immobilize the
SH2 variants (His-beads). The heat map displays a cluster of 427 proteins, which showed a log2-fold enrichment two times
greater for Fyn-SH2.s compared with the His-beads control. The heat scale depicts changes in fold enrichment relative to FynSH2.s.

For selection of Fyn-SH2 variants, each biotinylated pTyr peptide was immobilized in 96-well NuncImmuno MAXISORP plates (Thermo Scientiﬁc)
coated with streptavidin (New England Biolabs), and
phage pools representing the libraries were cycled
through ﬁve rounds of binding selections with the
immobilized pTyr peptide, as described.44 Phage ELISAs were performed to identify positive clones able to
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bind to the biotinylated pTyr peptide but not to streptavidin, and the amino acid sequences of positive
Fyn-SH2 variants were decoded by DNA sequencing.

Puriﬁcation of Fyn-SH2 variant proteins
Plasmids encoding SH2 domains fused to the Cterminus of glutathione S-transferase (GST) were
transformed into Escherichia coli BL21(DE3), and
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single colonies were used to inoculate 5 mL 2YT
medium containing 0.1 mg/mL carbenicillin. Cultures
were grown overnight at 37 C with 200 rpm shaking,
diluted 1:200 in 2YT medium containing 0.1 mg/mL
carbenicillin, grown at 37 C with 200 rpm shaking to
OD600 0.6–0.8, and induced with 0.1 mM IPTG at
18 C with 200 rpm shaking for 18 h. Cultures were
pelleted and resuspended in 10 mL Lysis Buffer
(50 mM Tris–HCl pH 7.8, 300 mM NaCl, 1 mM Phenylmethylsulfonyl ﬂuoride (PMSF), and protease
inhibitor cocktail (Sigma-Aldrich)). Cells were lysed
by sonication, and protein puriﬁcation was performed
by standard methods with Ni-NTA resin (Qiagen),
eluting proteins with an imidazole buffer gradient
ranging from 30 to 300 mM. The purity of eluted fractions was assessed by SDS-PAGE, and the buffer was
exchanged by dialysis at 4 C into PBS pH 7.4. Protein concentrations were determined from OD280
measurements with extinction coefﬁcient from
ExPASy ProtParam.45

Peptide synthesis
Solid phase peptide synthesis was performed using
9-ﬂuorenylmethoxycarbonyl chemistry on Rink amide
MBHA resin (Novabiochem) on a Prelude peptide
synthesizer (Protein Technologies, Inc.). Each peptide
N-terminus was functionalized directly with 5-(and6)-carboxyﬂuorescein (ThermoFisher Scientiﬁc) or
with biotin through a linker composed of two
ε-aminocaproic acids (Bachem). All peptides were
puriﬁed using C-18 reverse phase HPLC (Waters)
and authenticity was conﬁrmed by mass spectrometry on an Orbitrap Elite (ThermoFisher). Unless
stated otherwise, peptide sequences were derived
from human proteins.

Fluorescence polarization binding experiments
Binding measurements were performed in a 96-well
plate in FP buffer (20 mM HEPES pH 7.5, 150 mM
NaCl, 1 mM EDTA, 0.01 mg/mL BSA, 0.3% BRIJ-35)
by mixing 20 nM FITC-labeled pTyr peptide with
serial dilutions of Fyn-SH2 variant protein ranging
from 0.5 to 9 μM. For Fyn-SH2.wt or superbinder
Fyn-SH2 variants, the concentrations ranged from
0.1 to 1.8 μM or 0.023 to 2 μM, respectively. Samples
were equilibrated at room temperature for 30 min
before reading plates on an Analyst HT Plate Reader
(Molecular Devices) using an excitation ﬁlter of
485 nm and an emission ﬁlter of 530 nm. Dissociation
constants were determined with Prism (GraphPad
Software Inc) using a one-site total binding model.

Cell culture
HeLa cells were from American Type Culture Collection and were grown at 37 C with 5% CO2 in Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Life
Technologies) containing 10% (vol/vol) FBS (Sigma-
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Aldrich) and 50 U/mL penicillin and 50 μg/mL streptomycin (Sigma-Aldrich).

Phosphoproteome enrichment with SH2 variants
HeLa cells were treated with 1 mM sodium orthovanadate (Sigma), incubated at 37 C with 5% CO2 for
20 min, and washed twice with ice cold PBS. Upon
addition of Lysis buffer (20 mM HEPES pH 8.0, 8 M
urea, and phosphatase inhibitors (ThermoFisher Scientiﬁc), HeLa cells were scraped from plates, gently
sonicated, and spun at 15,000g for 15 min at 4 C to
remove cell debris. Supernatant was collected and
reduced by addition of 5 mM Tris(2-Carboxyethyl)
phosphine hydrochloride (TCEP) (Sigma) for 60 min
at 55 C prior to alkylation with 10 mM
2-Chloroacetamide (Sigma) for 15 min at room temperature in the dark. For enrichment of pTyr peptides following alkylation, protein extracts were
digested overnight at room temperature in 50 mM
ammonium bicarbonate pH 8.5 by adding 25 μg
TPCK-trypsin (Pierce) per 100 μg protein.
Digested peptides were quantiﬁed by BCA assay
(Pierce), and buffer was evaporated by centrifugation
at 25 C for 20 min using a Savant™ SPD131DDA
SpeedVac™ Concentrator (ThermoFisher Scientiﬁc).
Samples were resuspended in 100 mM Triethylammonium bicarbonate buffer (TEAB) pH 8.5, split into
10 vials and labeled for 1 h at room temperature with
amine-reactive 10-multiplex tandem mass tags
(TMT) (ThermoFisher Scientiﬁc) according to the
manufacturer’s instructions. The reaction was
quenched by addition of 5% hydroxylamine (Sigma)
for 15 min at room temperature. TMT-labeled peptides were pooled together in one vial and stored
at −80 C.
To isolate TMT-labeled pTyr peptides, 50 μg Histagged Fyn-SH2 variant protein was immobilized
onto 25 μL Ni-NTA agarose resin (Qiagen) previously
equilibrated with 1 mL binding buffer (50 mM
Na2HPO4 pH 7.4, 50 mM NaCl). 100 μg TMT-labeled
peptides were applied to each bead-immobilized FynSH2 variant and incubated with end-over-end rotation for 4 h. Beads were collected by centrifugation at
2000g at 4 C for 5 min and washed three times with
1 mL binding buffer. Bound TMT-labeled pTyr peptides were eluted from beads by addition of 50 μL
binding buffer containing 50 mM phenylphosphate
(Sigma) (Elution buffer). Samples were incubated in
elution buffer for 10 min at room temperature, and
eluted pTyr peptides were collected following precipitation of Ni-NTA beads by centrifugation at 2000g for
5 min at 4 C. pTyr peptides were transferred to a
new tube and adjusted to 1% TFA (Sigma).
To assess enrichment of phosphorylated proteins
by Fyn-SH2 variants, cell extracts were prepared as
described above. Following protein reduction and
alkylation, samples were subjected to afﬁnity puriﬁcation by applying 2 mg cell extract to Fyn-SH2
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variants immobilized onto Ni-NTA agarose resin as
previously described. As a control, cell extracts were
loaded onto empty Ni-NTA beads (His beads) and
beads previously immobilized with 50 μg anti-pTyr
antibody. After incubation for 3 h and elution as
described above, samples were digested with TPCKtrypsin and labeled with 10-multiplex TMT labels as
described above. TMT-labeled peptides were pooled
together and adjusted to 1% TFA. Following the
enrichment step, the pTyr peptide mixtures were
desalted and concentrated using C18 Ziptips (Sigma)
according to manufacturer’s instructions and stored
at −80 C.

LC–MS/MS analysis
MS analysis was performed on an Orbitrap Elite
mass spectrometer (ThermoFisher Scientiﬁc) coupled
to an EASY nlC 1000 chromatography system
(ThermoFisher Scientiﬁc). Peptides were separated
by liquid chromatography with a 2-μm C18 column
(Thermo Scientiﬁc) at a ﬂow rate of 250 nL/min for
120 min using a 0–40% acetonitrile gradient. Eluted
peptides were injected into the mass spectrometer,
and data were acquired at a 70,000 resolution with a
m/z 400. Mass spectra were acquired in full scan
mode with HCD (high-energy collision dissociation)
fragmentation. Acquired data were analyzed by MaxQuant software46 for identiﬁcation and quantiﬁcation
on Swiss-Prot database.
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